Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

PARMA, Italy & CAMBRIDGE, MA, June 25, 2026 — Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced a milestone for ABO-101, an investigational gene Read More The post Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria appeared first on Arbor Biotechnologies .